Clinical significance of E2A/PBX1 fusion gene in childhood acute lymphoblastic leukemia
Zhu Yingying
Song Lili
Shi Lihuan
Li Yange
Liu Wei
Abstract：Objective To investigate the clinical significance of E2A/PBX1 fusion gene measurement in childhood acute lymphoblastic leukemia (ALL).Methods E2A/PBX1 fusion gene was evaluated by nested reverse transcription polymerase chain reaction (RT-PCR) in 523 newly B-ALL childhood patients from January 2010 to June 2014.26 patients were identified as E2A/PBX1(4.97%, 26/523 cases), including 21 patients classfied to the intermediate-risk group, and at the same time 43 cases with negative E2A/PBX1 fusion gene were regarded as control group.The clinical characteristics at diagnosis, 5-year event-free survival(EFS) rate and overall survival(OS) rate in the two groups were analyzed.Results There were no significant differences between the two group in gender, age, initial white blood cell count, hemoglobin level and platelet count.Statistic differences were not found in minimal residual disease(MRD) level at day 33 after induction treatment, 5-year EFS rates (81.0% vs 78.6%) and OS rates (85.7% vs 83.3%) between two groups(all P>0.05).Conclusion The prognosis can be improved through intense chemotherapy for ALL childhood patients with E2A/PBX1 fusion gene.At intermediate-risk group, statistic differences were not found in clinical characteristics, response to early treatment and prognosis between the E2A/PBX1 positive and negative patients.E2A/PBX1 fusion gene palys an intermediate-risk role in B-ALL childhood patients.
Keywords：acute lymphoblastic leukemiachildE2A/PBX1 fusion geneprognosis
Publication Date：2017-01-01
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：4( 1732-1735 )